Novartis Breaks Through with Radioligand Therapy for Prostate Cancer

Novartis has a lot to be excited about going into this year’s American Society of Clinical Oncology (ASCO) meeting, and the highlight is the company’s targeted radioligand therapy (RLT) platform, 177Lu-PSMA-617, which has demonstrated considerable promise in PSMA-positive metastatic castration-resistant prostate cancer.